Protocol Ledger

NCT05997017 · Phase II · RECRUITING

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

Interventional Phase II clinical trial protocol NCT05997017 sponsored by Aadi Bioscience in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-28 Enrollment: 29 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05997017
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)29 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05997017
Protocol FieldVerified Registry Value
NCT IdentifierNCT05997017
Consolidated Lead SponsorAadi Bioscience
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment29 participants (ESTIMATED)
Registered Start Date2023-12-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05997017
Hospital Research SiteLocationSite Profile
Memorial Sloan Kettering Cancer CenterNew York, NYOpen Hospital Dossier ->
Levine Cancer InstituteCharlotte, NCOpen Hospital Dossier ->
Texas Oncology (Tyler)Tyler, TXOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI